We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Exact Sciences (EXAS - Free Report) . Shares have lost about 39.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Exact Sciences Registers Strong Q3 Revenues On Robust Cologuard Volume
Exact Sciences’ third quarter 2019 net loss came in at 31 cents per share, narrower than the year-ago loss of 37 cents as well as the Zacks Consensus Estimate of loss of 41 cents.
Revenues came in at $218.8 million, a 85% surge from the year-ago period.
Cologuard test volume was 456,000, up 89% year- over year.
In the third quarter, estimated Cologuard market share, including the expanded label to average risk Americans ages 45-49 years old, was 5.2%.
However, Average Cologuard recognized revenue per test was $479 a drop of $13 from the year-ago recognized revenue per test. On the other hand, average Cologuard cost per test of $114, reported an increase of $10 per test.
Gross margin in the third quarter expanded 130 basis points (bps) to 76%. However, the company incurred loss from operations of $35.7 million in the quarter compared to year-ago loss of $40.9 million.
Outlook
Excluding the impact of the Genomic Health consolidation, the company anticipates revenue of $802-$810 million during 2019. The company's revenue guidance does not include the impact of the pending combination with Genomic Health.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -206.55% due to these changes.
VGM Scores
At this time, Exact Sciences has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exact Sciences (EXAS) Down 39.7% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Exact Sciences (EXAS - Free Report) . Shares have lost about 39.7% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Exact Sciences due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Exact Sciences Registers Strong Q3 Revenues On Robust Cologuard Volume
Exact Sciences’ third quarter 2019 net loss came in at 31 cents per share, narrower than the year-ago loss of 37 cents as well as the Zacks Consensus Estimate of loss of 41 cents.
Revenues came in at $218.8 million, a 85% surge from the year-ago period.
Cologuard test volume was 456,000, up 89% year- over year.
In the third quarter, estimated Cologuard market share, including the expanded label to average risk Americans ages 45-49 years old, was 5.2%.
However, Average Cologuard recognized revenue per test was $479 a drop of $13 from the year-ago recognized revenue per test. On the other hand, average Cologuard cost per test of $114, reported an increase of $10 per test.
Gross margin in the third quarter expanded 130 basis points (bps) to 76%. However, the company incurred loss from operations of $35.7 million in the quarter compared to year-ago loss of $40.9 million.
Outlook
Excluding the impact of the Genomic Health consolidation, the company anticipates revenue of $802-$810 million during 2019. The company's revenue guidance does not include the impact of the pending combination with Genomic Health.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a downward trend in estimates review. The consensus estimate has shifted -206.55% due to these changes.
VGM Scores
At this time, Exact Sciences has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Following the exact same course, the stock was allocated a grade of D on the value side, putting it in the bottom 40% for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Exact Sciences has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.